Story perspectives

UK Regulator Reviews Medication Warnings After Impulse-Control Study

3/28/2026

Summary

Story summary

The UK Medicines and Healthcare products Regulatory Agency (MHRA) is reviewing impulse-control warnings on related medications after a British Broadcasting Corporation (BBC) investigation found misleading leaflets.
A study found 17% of Parkinson's patients on dopamine agonists experience impulse control disorders, contradicting leaflets calling these effects 'uncommon'.
Families affected by gambling and sexual addictions express outrage over insufficient warnings.
Experts say accurate information is crucial for patient safety and treatment decisions.

1 of 1

Story summary

The UK Medicines and Healthcare products Regulatory Agency (MHRA) is reviewing impulse-control warnings on related medications after a British Broadcasting Corporation (BBC) investigation found misleading leaflets.
A study found 17% of Parkinson's patients on dopamine agonists experience impulse control disorders, contradicting leaflets calling these effects 'uncommon'.
Families affected by gambling and sexual addictions express outrage over insufficient warnings.
Experts say accurate information is crucial for patient safety and treatment decisions.